Shares of Kenvue Inc. KVUE shed 1.42% to $23.66 Tuesday, on what proved to be an all-around mixed trading session for the ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

Kenvue Inc. has announced the appointment of Amit Banati as chief financial officer, effective today. He will be responsible ...

Kenvue on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a ...

Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter ...

The leadership change comes at the end of a week in which the California-based toymaker landed squarely in the crosshairs of ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Kenvue Inc. reported second-quarter earnings that surpassed analyst estimates, while updating its full-year 2025 guidance to account for tariffs and currency headwinds.

Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSofya Tsinis - Head of Investor RelationsThibaut ...

Shares of Kenvue Inc. KVUE slid 1.80% to $24.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 3.26% to 5,844.19 and the ...